Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in HFpEF (EMPEROR-Preserved)
NCT03057951Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2017
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of empagliflozin in heart failure with preserved ejection fraction (HFpEF), sponsored by Boehringer Ingelheim. Started Mar 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03057951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03057951.